Amirreza Haghighi
Overview
Explore the profile of Amirreza Haghighi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
434
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calvaruso L, Yau K, Akbari P, Nasri F, Khowaja S, Wang B, et al.
Sci Rep
. 2023 Dec;
13(1):22257.
PMID: 38097698
Tolvaptan is the first disease-modifying drug proven to slow eGFR decline in high-risk patients with ADPKD. However, barriers from the patient perspective to its use in real-life settings have not...
2.
Haghighi A, Alvandi Z, Nilipour Y, Haghighi A, Kornreich R, Nafissi S, et al.
Eur J Hum Genet
. 2023 Jul;
31(11):1237-1250.
PMID: 37460656
Nemaline myopathy (NM) is a heterogeneous genetic neuromuscular disorder characterized by rod bodies in muscle fibers resulting in multiple complications due to muscle weakness. NM patients and their families could...
3.
Iliuta I, Win A, Lanktree M, Lee S, Pourafkari M, Nasri F, et al.
Sci Rep
. 2023 Feb;
13(1):2952.
PMID: 36807559
Using age- and height-adjusted total kidney volume, the Mayo Clinic Imaging Classification provides a validated approach to assess the risk of chronic kidney disease (CKD) progression in autosomal dominant polycystic...
4.
Rocchetti M, Pesce F, Matino S, Piscopo G, di Bari I, Trepiccione F, et al.
J Nephrol
. 2022 Nov;
36(4):987-997.
PMID: 36342644
Background: Age- and height-adjusted total kidney volume is currently considered the best prognosticator in patients with autosomal dominant polycystic kidney disease. We tested the ratio of urinary epidermal growth factor...
5.
Iliuta I, Song X, Pickel L, Haghighi A, Retnakaran R, Scholey J, et al.
Front Mol Biosci
. 2022 Sep;
9:962933.
PMID: 36106024
Autosomal dominant polycystic kidney disease (ADPKD) is the most common Mendelian kidney disease, affecting approximately one in 1,000 births and accounting for 5% of end-stage kidney disease in developed countries....
6.
Lanktree M, Guiard E, Akbari P, Pourafkari M, Iliuta I, Ahmed S, et al.
Clin J Am Soc Nephrol
. 2021 Feb;
16(3):374-383.
PMID: 33602752
Background And Objectives: Progression of autosomal dominant polycystic kidney disease (ADPKD) is highly variable. On average, protein-truncating mutations are associated with the most severe kidney disease among all mutation classes....
7.
Lanktree M, Haghighi A, di Bari I, Song X, Pei Y
Clin J Am Soc Nephrol
. 2020 Jul;
16(5):790-799.
PMID: 32690722
Autosomal dominant polycystic kidney disease is the most common monogenic cause of ESKD. Genetic studies from patients and animal models have informed disease pathobiology and strongly support a "threshold model"...
8.
Magayr T, Song X, Streets A, Vergoz L, Chang L, Valluru M, et al.
Kidney Int
. 2020 Jul;
98(2):420-435.
PMID: 32622528
MicroRNAs (miRNAs) play an important role in regulating gene expression in health and disease but their role in modifying disease expression in Autosomal Dominant Polycystic Kidney Disease (ADPKD) remains uncertain....
9.
Lanktree M, Guiard E, Li W, Akbari P, Haghighi A, Iliuta I, et al.
Kidney Int Rep
. 2019 Jul;
4(7):995-1003.
PMID: 31317121
Introduction: Discordance in kidney disease severity between affected relatives is a recognized feature of autosomal dominant polycystic kidney disease (ADPKD). Here, we report a systematic study of a large cohort...
10.
Yao T, Udwan K, John R, Rana A, Haghighi A, Xu L, et al.
Clin J Am Soc Nephrol
. 2019 Jan;
14(2):213-223.
PMID: 30647093
Background And Objectives: FSGS and nephrotic syndrome studies have shown that single gene causes are more likely to be found in pediatric cases than adults. Consequently, many studies have examined...